Semaglutide in the ESSENCE Trial: A Breakthrough for Liver Disease Treatment?
Liver disease, especially metabolic dysfunction-associated steatohepatitis (MASH), has long been a silent threat, affecting millions of people globally. Often progressing…
Tag: Drugs
What is GLORY-1?
GLORY-1 is an innovative investigational therapy in the field of metabolic health, designed as a dual receptor agonist targeting both…
China’s Breakthrough Obesity Drug Mazdutide Achieves Record Weight Loss in Global Study
A landmark Phase 3 clinical study of mazdutide, the world’s first dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, has been…
Top Obesity Drug Stocks to Watch: The Companies Leading the Weight-Loss Revolution
The global obesity drug market is experiencing significant growth, with projections exceeding $150 billion annually in the coming decade. This…
Weight-Loss Jabs Could Slash Cancer Risk by 50%: A “Transformational” Breakthrough
Key Findings at a Glance The Study: How Weight-Loss Drugs Stack Up Against Surgery A landmark Israeli study (presented at the European Congress…
Tirzepatide vs. Semaglutide for Obesity: Which Weight-Loss Drug Works Better?
New SURMOUNT-5 Trial Results (2025) Key Takeaways ✅ Tirzepatide (Zepbound) led to significantly greater weight loss than semaglutide (Wegovy). Background: The…
If You’re 20+, These Tests Can Help You Avoid Obesity (And Its Hidden Risks)
Obesity doesn’t happen overnight—it creeps in due to metabolic, hormonal, and lifestyle changes that start in your 20s. Catching early warning signs…